• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results

    Prellis Biologics' New Tool Simplifies Complex Tissue Engineering

    InspireMD's CEO Steps Down

    Celmatix Sues Research Partner 23andMe for $100M

    FDA Cleared New Cochlear Osia 2 System
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    From Genome Sequencing to the World’s First Portable MRI

    An Update on Digital Health

    ‘If You’re Reading This, You Need to Be at This Meeting’

    Five Steps for Succeeding Globally in Medtech

    Unlocking Market Doors with Real-World Evidence
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    GS Plastic Optics

    Nelson Laboratories LLC

    Marox Corporation

    Eurofins Medical Device Testing

    K-Tube Technologies
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    EU's MDR: Irresistible Force Meets Immovable Object

    Ladies First: An Examination of the Women's Health Device Industry

    Localizing Medical Devices

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Understanding Key Processes for Mixing APIs with Silicone
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    RJG Inc.

    NN Life Sciences/Paragon Medical

    DELMIAWORKS (IQMS)

    Eurofins Medical Device Testing

    K-Tube Technologies
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Theranos Founder, Former Chief Operating Officer Charged With Alleged Wire Fraud

    Pair accused of perpetrating multi-million dollar schemes to defraud investors, doctors, and patients.

    Theranos Founder, Former Chief Operating Officer Charged With Alleged Wire Fraud
    A federal grand jury has indicted Elizabeth A. Holmes with two counts of conspiracy to commit wire fraud and nine counts of wire fraud. She also has stepped down as Theranos CEO.
    Related CONTENT
    • Abbott's FreeStyle Libre Glucose Monitoring System Available to Medicare Patients
    • Theranos’ Holmes and Former President Balwani Charged with Massive Fraud
    • FDA Restricts Sale and Distribution of Essure Birth Control Implant
    • FDA's Expansion of 510(k) Program Seeks to End Predicate Testing for Some Devices
    • FDA Finalizes Guidances to Speed Development of Next-Generation Sequencing Based Tests
    U.S. Department of Justice06.18.18
    A federal grand jury has indicted Elizabeth A. Holmes and Ramesh “Sunny” Balwani on two counts of conspiracy to commit wire fraud and nine counts of wire fraud, announced Acting United States Attorney Alex G. Tse, Federal Bureau of Investigation (FBI) Special Agent in Charge John F. Bennett; U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb; and U.S. Postal Inspection Service (USPIS) Inspector in Charge Rafael Nuñez. 

    According to a June 14 indictment, the charges stem from allegations Holmes and Balwani engaged in a multi-million dollar scheme to defraud investors, and a separate scheme to defraud doctors and patients.  Both schemes involved efforts to promote Palo Alto, Calif.-based Theranos.   
     
    Holmes, 34, of Los Altos Hills, Calif., founded Theranos in 2003. Theranos is a private health care and life sciences company with the stated mission to revolutionize medical laboratory testing through allegedly innovative methods for drawing blood, testing blood, and interpreting the resulting patient data. Balwani, 53, of Atherton, Calif., was employed at Theranos from September of 2009 through 2016. At times during that period, Balwani worked in several capacities including as a member of the company’s board of directors, as its president, and as its chief operating officer. 

    Holmes has stepped down as Theranos CEO but remains its founder and board chairman, according to an official company statement. General Counsel David Taylor is replacing Holmes as chief executive.

    According to the indictment, Holmes and Balwani used advertisements and solicitations to encourage and induce doctors and patients to use Theranos’s blood testing laboratory services, even though the defendants knew Theranos was not capable of consistently producing accurate and reliable results for certain blood tests. The tests performed on Theranos technology, in addition, were likely to contain inaccurate and unreliable results. 

    “This indictment alleges a corporate conspiracy to defraud financial investors,” said Special Agent in Charge Bennett.  “This conspiracy misled doctors and patients about the reliability of medical tests that endangered health and lives.”
     
    The indictment alleges that the defendants used a combination of direct communications, marketing materials, statements to the media, financial statements, models, and other information to defraud potential investors. Specifically, the defendants claimed that Theranos developed a revolutionary and proprietary analyzer that the defendants referred to by various names, including as the TSPU, Edison, or minilab. The defendants claimed the analyzer was able to perform a full range of clinical tests using small blood samples drawn from a finger stick. The defendants also represented that the analyzer could produce results that were more accurate and reliable than those yielded by conventional methods—all at a faster speed than previously possible. 
     
    The indictment further alleges that Holmes and Balwani knew that many of their representations about the analyzer were false. For example, allegedly, Holmes and Balwani knew that the analyzer, in truth, had accuracy and reliability problems, performed a limited number of tests, was slower than some competing devices, and, in some respects, could not compete with existing, more conventional machines.
     
    “The conduct alleged in these charges erodes public trust in the safety and effectiveness of medical products, including diagnostics. The FDA would like to extend our thanks to our federal law enforcement partners for sending a strong message to Theranos executives and others that these types of actions will not be tolerated,” said Catherine A. Hermsen, acting director, FDA Office of Criminal Investigations.

    “The United States Postal Inspection Service has a history of successfully investigating complex fraud cases,” said Nuñez. “Anyone who engages in deceptive practices should know they will not go undetected and will be held accountable.”
     
    Doctors And Patients Allegedly Defrauded
    The indictment alleges Holmes and Balwani defrauded doctors and patients by making false claims concerning Theranos’s ability to provide accurate, fast, reliable, and cheap blood tests and test results, and through omissions concerning the limits of and problems with Theranos’s technologies. The defendants knew Theranos was not capable of consistently producing accurate and reliable results for certain blood tests, including the tests for calcium, chloride, potassium, bicarbonate, HIV, Hba1C, hCG, and sodium. The defendants nevertheless used interstate electronic wires to purchase advertisements intended to induce individuals to purchase Theranos blood tests at Walgreens stores in California and Arizona. Through these advertisements, the defendants explicitly represented to individuals that Theranos’s blood tests were cheaper than blood tests from conventional laboratories to induce individuals to purchase Theranos’s blood tests. 
     
    Further, the indictment alleges that based on the defendants’ misrepresentations and omissions, many hundreds of patients paid, or caused their medical insurance companies to pay, Theranos, or Walgreens acting on behalf of Theranos, for blood tests and test results, sometimes following referrals from their defrauded doctors. In addition, the defendants delivered to doctors and patients blood results that were inaccurate, unreliable, and improperly validated. The defendants also delivered to doctors and patients blood test results from which critical results were improperly removed.
     
    The indictment describes a number of schemes that defendants allegedly employed to mislead investors, doctors, and patients. For example, with respect to investors, defendants performed technology demonstrations during which defendants intended to cause potential investors to believe blood tests were being conducted on Theranos’s proprietary analyzer when, in fact, the analyzer really was running a “null protocol”  and was not testing the potential investor’s blood. Similarly, defendants purchased and used commercially-available analyzers to test patient blood, while representing to investors that Theranos conducted its patients’ tests using Theranos-manufactured analyzers. 
     
    Investors Duped As Well
    According to the indictment, the defendants also allegedly made numerous misrepresentations to potential investors about Theranos’s financial condition and its future prospects. For example, the defendants represented to investors that Theranos conducted its patients’ tests using Theranos-manufactured analyzers; when, in truth, Holmes and Balwani knew that Theranos purchased and used for patient testing third party, commercially-available analyzers. The defendants also represented to investors that Theranos would generate over $100 million in revenues and break even in 2014 and that Theranos expected to generate approximately $1 billion in revenues in 2015 when, in truth, the defendants knew Theranos would generate only negligible or modest revenues in 2014 and 2015. 
     
    Further, defendants allegedly represented to investors that Theranos had a profitable and revenue-generating business relationship with the U.S. Department of Defense and that Theranos’s technology had deployed to the battlefield when, in truth, Theranos had limited revenue from military contracts and its technology was not deployed in the battlefield. In addition, the defendants represented to investors that Theranos would soon dramatically increase the number of Wellness Centers within Walgreens stores when, in truth, Holmes and Balwani knew by late 2014 that Theranos’s retail Walgreens rollout had stalled because of several issues, including that Walgreens’s executives had concerns with Theranos’s performance.
     
    An indictment merely alleges that crimes have been committed, and the defendants are presumed innocent until proven guilty beyond a reasonable doubt. 
     
    The indictment charges Holmes and Balwani with two counts of conspiracy to commit wire fraud and nine counts of wire fraud.  If convicted, the pair face a maximum 20-year prison term and $250,000 fine, plus restitution, for each count of wire fraud and for each conspiracy count. 
     
    Both defendants appeared on June 15 before U.S. Magistrate Judge Susan van Keulen for their initial appearances. The matter was assigned to the Honorable Lucy H. Koh, U.S. District Judge, for further proceedings. 
     
    Assistant U.S. Attorneys Jeff Schenk, Robert S. Leach, and John C. Bostic are prosecuting the case with the assistance of Laurie Worthen and Bridget Kilkenny. The prosecution is the result of an investigation by the FDA Office of Criminal Investigations, the FBI, and the U.S. Postal Inspection Service.
    Related Searches
    • u.s. food and drug administration
    • technologies
    • health
    • 2015
    Suggested For You
    FDA Green Lights Trial for RENOVA iStim Tibial Nerve Neuromodulator for Overactive Bladder FDA Green Lights Trial for RENOVA iStim Tibial Nerve Neuromodulator for Overactive Bladder
    Empirical Machine Earns FDA Contract Manufacturer Designation Empirical Machine Earns FDA Contract Manufacturer Designation
    FDA OKs Label Change for Apollo Endosurgery FDA OKs Label Change for Apollo Endosurgery's ORBERA Intragastric Balloon
    FDA Initiates Device Development Challenge to Help Combat Opioid Crisis FDA Initiates Device Development Challenge to Help Combat Opioid Crisis
    3 Critical Considerations for U.S. Medical Device Commercialization 3 Critical Considerations for U.S. Medical Device Commercialization
    FDA Seeks Permanent Injunctions Against Two Stem Cell Clinics FDA Seeks Permanent Injunctions Against Two Stem Cell Clinics
    Theranos: Not Long for the Business World? Theranos: Not Long for the Business World?
    Driving Innovation and Improving Quality with 3D Printing Driving Innovation and Improving Quality with 3D Printing
    Quality Nightmares #38: Audit Selection Quality Nightmares #38: Audit Selection
    Software Validation: How It Should Be Done Software Validation: How It Should Be Done
    FDA Authorizes First Test for Emerging Pathogen Candida Auris FDA Authorizes First Test for Emerging Pathogen Candida Auris
    FDA Finalizes Guidances to Speed Development of Next-Generation Sequencing Based Tests FDA Finalizes Guidances to Speed Development of Next-Generation Sequencing Based Tests
    FDA FDA's Expansion of 510(k) Program Seeks to End Predicate Testing for Some Devices
    FDA Restricts Sale and Distribution of Essure Birth Control Implant FDA Restricts Sale and Distribution of Essure Birth Control Implant
    Theranos’ Holmes and Former President Balwani Charged with Massive Fraud Theranos’ Holmes and Former President Balwani Charged with Massive Fraud

    Related Breaking News

    • Digital Health | Software & IT
      15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results

      15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results

      Florida’s first eICU, powered by Philips telehealth technology, touts reduced mortality rates and hospital stays for the sickest patients.
      GlobeNewswire 12.11.19

    • 3D/Additive Manufacturing | Software & IT
      Prellis Biologics

      Prellis Biologics' New Tool Simplifies Complex Tissue Engineering

      TissueWorkshop generates complex 3D scaffolds that can be printed with any 3D printing system.
      Krause Taylor Associates 12.11.19

    • InspireMD

      InspireMD's CEO Steps Down

      New CEO Marvin Slosman, a life sciences industry veteran, joins InspireMD from Integra LifeSciences.
      GlobeNewswire 12.11.19


    • Celmatix Sues Research Partner 23andMe for $100M

      Celmatix Sues Research Partner 23andMe for $100M

      Celmatix claims breaches of the parties' agreement and tortious interference with efforts to raise capital.
      PR Newswire 12.11.19

    • FDA Cleared New Cochlear Osia 2 System

      FDA Cleared New Cochlear Osia 2 System

      The world’s first active osseointegrated steady-state implant.
      Cochlear 12.11.19

    • Neurological
      FDA Approves First Nasal Rescue Treatment for Frequent Seizure Activity

      FDA Approves First Nasal Rescue Treatment for Frequent Seizure Activity

      Aptar’s Unidose Liquid System can deliver a formulation in an emergency situation quickly and easily and be administered by a non-healthcare professional.
      Business Wire 12.10.19


    • Diagnostics
      Lens-Free Microendoscope Generates High Quality Images

      Lens-Free Microendoscope Generates High Quality Images

      It also doesn't require movement to focus on objects at different depths.
      Johns Hopkins University 12.10.19

    • Patient Monitoring | Software & IT
      Roche

      Roche's Blood Glucose Reading Smartphone App Gains CE Mark

      The app determines blood glucose ranges by taking photos with the smartphone camera without the need for a blood glucose meter.
      GlobeNewswire 12.10.19

    • FDA BDP Designation for the iLet Bionic Pancreas System

      FDA BDP Designation for the iLet Bionic Pancreas System

      The world’s first fully automated bionic pancreas.
      Beta Bionics 12.10.19


    • Diagnostics
      NeuMoDx Molecular and Sentinel Diagnostics Partner

      NeuMoDx Molecular and Sentinel Diagnostics Partner

      Work together to develop multiple new assays for the NeuMoDx Molecular Systems.
      NeuMoDx Molecular 12.10.19

    • Neural Analytics Enrolls First Patient With Its Next-Generation Lucid Robotic System

      Neural Analytics Enrolls First Patient With Its Next-Generation Lucid Robotic System

      The new IDE version of the technology is intended to improve performance and ease of use for the company’s robotic platform.
      Business Wire 12.10.19

    • Cardiovascular | Neurological
      Imperative Care Closes a Series C Financing of $85 Million for Stroke Treatments

      Imperative Care Closes a Series C Financing of $85 Million for Stroke Treatments

      The funds will support the commercial launch of the company’s portfolio.
      Imperative Care Inc. 12.10.19

    • Contract Manufacturing
      Medical Murray Holds Open House

      Medical Murray Holds Open House

      Event centered around new 35,000 square foot facility.
      Medical Murray 12.10.19

    • Cardiovascular
      FDA Grants Supplemental-PMA Approval to Impulse Dynamics

      FDA Grants Supplemental-PMA Approval to Impulse Dynamics' Next-Generation Optimizer Smart System

      Product offers a new therapy for heart failure patients with reduced ejection fraction.
      Businesswire 12.10.19

    • OmniGuide Holdings Expands Executive Team

      OmniGuide Holdings Expands Executive Team

      Company hires global marketing VP and managing director of Surgical Strategic Business Unit.
      Businesswire 12.10.19


    Breaking News
    • 15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results
    • Prellis Biologics' New Tool Simplifies Complex Tissue Engineering
    • InspireMD's CEO Steps Down
    • Celmatix Sues Research Partner 23andMe for $100M
    • FDA Cleared New Cochlear Osia 2 System
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • Adding Fabrication Capabilities: Additive Manufacturing for Production Parts
    • Delivering the Goods: The Evolving World of Combination Products
    • Anxious Undertones: The 2019 Year in Review
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Beckers Group Announces Global Price Increase on Coil, Industrial Coatings
    Evonik, Wynca Celebrate Groundbreaking of New Fumed Silica Plant in Zhenjiang
    Personnel Changes in Corporate Communications, Government Relations at BASF
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results
    Prellis Biologics' New Tool Simplifies Complex Tissue Engineering
    InspireMD's CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    CatSci Expands Capabilities with Lab Expansion
    Smart Tags on Pills Set to Improve Supply Chain Security and Patient Adherence
    PCI Pharma Services Invests in Tredegar, UK Site
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Star of E!'s Botched Gets Line Leaping Bunny Certified
    Happi

    Latest Breaking News From Happi

    Birchbox Partners with Buzzfeed
    Coty Strengthens Its Leadership
    Jennifer Garner Joins Virtue Labs
    Ink World

    Latest Breaking News From Ink World

    Smurfit Kappa, Wings for Aid Create Disaster Relief Packaging Solution
    ePac Flexible Packaging Expands into Asia Pacific Market
    United Carton Industries Company Invests in EFI Nozomi Corrugated Printer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Mark Andy joins forces with UPM Raflatac
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Simavita Set to License Sensor Technology in EU
    NDC Appoints President
    AATC Adds Two Scholarships
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    TriMed Closes Out FDA Warning Letter
    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Releases Global Semiconductor Equipment Sales Forecast
    eMagin Corporation Announces Approximately $4.3 Million Order for Military Program
    CPI Supports Smart Food-labeling Project Set to Reduce Food Waste in 2020

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.